Thursday , September 21 2017
Home / Specialty Pharmacy

Specialty Pharmacy

Anthem, Inc. to Acquire HealthSun

INDIANAPOLIS–(BUSINESS WIRE)–Anthem, Inc. (NYSE:ANTM) today announced that the company has entered into an agreement to acquire HealthSun, one of the fastest-growing integrated Medicare Advantage health plans and healthcare delivery networks in Florida. “Anthem is committed to identifying opportunities for growth that will enable us to advance our goal of increasing …

Read More »

Genentech’s Actemra Receives FDA Approval for the Treatment of CAR-T Cell-Induced Cytokine Release Syndrome

South San Francisco, CA — August 30, 2017 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra®(tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release …

Read More »

FDA Approves Teva’s Austedo for Treatment of Tardive Dyskinesia in Adults

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO® (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults. AUSTEDO® was previously approved for the treatment of chorea associated with Huntington’s disease in April 2017. Tardive dyskinesia is a …

Read More »

Biogen Announces New Data from Phase 1b Study of its Investigational Alzheimer’s Disease Drug

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen (NASDAQ: BIIB) today announced results from a recently conducted analysis of the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, the company’s investigational treatment for early Alzheimer’s disease. The updated analyses include data from the placebo-controlled period and LTE for patients treated with aducanumab up …

Read More »

FDA Approves Adamas’ Gocovri for the Treatment of Dyskinesia in Parkinson’s Disease Patients

EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) — Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI, previously granted orphan drug status by …

Read More »

FDA Approves Duzallo for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced DUZALLO was approved by the U.S. Food and Drug Administration (FDA) as a once-daily oral treatment for hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with a medically appropriate daily dose of allopurinol alone. …

Read More »

Samsung Bioepis and Takeda Collaborate for Development of Multiple Novel Biologic Therapies

INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. announced today that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company Limited (TSE: 4502) to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas. The two companies will immediately begin working on the program’s first therapeutic candidate, …

Read More »

FDA Approves Imbruvica as First and Only Approved Therapy for Patients with Chronic Graft-Versus-Host-Disease

HORSHAM, Pa., Aug. 2, 2017 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of adult patients with chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy.1 IMBRUVICA is the first and only FDA-approved medication for adult patients with …

Read More »

Genentech’s Actemra Demonstrates Positive Results in Phase 3 Study in Patients with Giant Cell Arteritis

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that data from the Phase III GiACTA study, which evaluated Actemra® (tocilizumab) in adult patients with GCA, were published in the July 27, 2017 issue of the New England Journal of Medicine. The primary …

Read More »

New Imaging Technique Able to Watch Molecular Dynamics of Neurodegenerative Diseases

WASHINGTON — Researchers have developed a fast and practical molecular-scale imaging technique that could let scientists view never-before-seen dynamics of biological processes involved in neurodegenerative diseases such as Alzheimer’s disease and multiple sclerosis. The new technique reveals a sample’s chemical makeup as well as the orientation of molecules making up …

Read More »